$RAPH
Raphael Pharmaceutical Inc.

2022 Q4 Form 10-Q Financial Statement

#000121390022071861 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $428.0K $1.094M
YoY Change
% of Gross Profit
Research & Development $676.0K $332.0K $161.0K
YoY Change 106.21%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.104M $332.0K $161.0K
YoY Change 106.21%
Operating Profit -$1.426M -$418.0K
YoY Change 241.15%
Interest Expense $1.000K -$17.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$17.00K $2.000K
YoY Change -950.0%
Pretax Income -$1.103M -$1.443M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$1.103M -$1.443M -$416.0K
YoY Change 246.88%
Net Earnings / Revenue
Basic Earnings Per Share $0.10 $0.03
Diluted Earnings Per Share -$0.07 $0.10 $0.03
COMMON SHARES
Basic Shares Outstanding 15.62M shares 15.23M shares 12.13M shares
Diluted Shares Outstanding 15.06M shares 12.13M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $288.0K $93.00K
YoY Change
Cash & Equivalents $288.0K $93.00K $37.00K
Short-Term Investments
Other Short-Term Assets $43.00K $26.00K
YoY Change -84.01%
Inventory
Prepaid Expenses $5.000K
Receivables
Other Receivables
Total Short-Term Assets $331.0K $119.0K
YoY Change -21.56%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $2.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $2.000K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $331.0K $119.0K
Total Long-Term Assets $2.000K $2.000K
Total Assets $333.0K $121.0K
YoY Change -21.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $224.0K
YoY Change
Accrued Expenses $152.0K
YoY Change -7.88%
Deferred Revenue
YoY Change
Short-Term Debt $3.000K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $227.0K $183.0K
YoY Change -22.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $227.0K $183.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $227.0K $183.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$6.025M -$4.922M
YoY Change 125.91%
Common Stock $157.0K $155.0K
YoY Change 20.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.0K -$62.00K
YoY Change
Total Liabilities & Shareholders Equity $333.0K $121.0K
YoY Change -21.09%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$1.103M -$1.443M -$416.0K
YoY Change 246.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$277.0K -$374.1K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $580.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 472.0K 416.3K
YoY Change
NET CHANGE
Cash From Operating Activities -277.0K -374.1K
Cash From Investing Activities 0.000 580.0
Cash From Financing Activities 472.0K 416.3K
Net Change In Cash 195.0K 42.82K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$277.0K -$374.1K
Capital Expenditures $0.00 $2.000K
Free Cash Flow -$277.0K -$376.1K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei City Area Code
CityAreaCode
(+972)
dei Local Phone Number
LocalPhoneNumber
52-775-5072
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53002
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15624040 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
26000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
269000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
119000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
422000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000 usd
CY2022Q3 us-gaap Assets
Assets
121000 usd
CY2021Q4 us-gaap Assets
Assets
422000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
183000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
272000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
22000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
183000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
294000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15484040 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15484040 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12970540 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12970540 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
155000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
130000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4705000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2665000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4922000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2667000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-62000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
422000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
502000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
552000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
332000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
161000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1711000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
503000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1094000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
257000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2213000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1055000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1426000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-418000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1058000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1443000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-416000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13921106 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10811014 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15061902 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12131663 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
128000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
512000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
290000 usd
us-gaap Net Income Loss
NetIncomeLoss
-812000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
118000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
63000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1200000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1443000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-62000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
370000 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
506000 usd
us-gaap Net Income Loss
NetIncomeLoss
-642000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
191000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-416000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-125000 usd
us-gaap Profit Loss
ProfitLoss
-2255000 usd
us-gaap Profit Loss
ProfitLoss
-1058000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1490000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-243000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-203000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
40000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
140000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-482000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-715000 usd
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
174000 usd
cik0000141539 Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
424000 usd
cik0000141539 Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
470000 usd
cik0000141539 Cash Acquired In The Reverse Recapitalization
CashAcquiredInTheReverseRecapitalization
13000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
424000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
657000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
93000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37000 usd
cik0000141539 Current Assetsexcluding Cash And Cash Equivalents
CurrentAssetsexcludingCashAndCashEquivalents
-531000 usd
cik0000141539 Current Liabilities
CurrentLiabilities
38000 usd
cik0000141539 Reverse Recapitalization Effect On Equity
ReverseRecapitalizationEffectOnEquity
506000 usd
cik0000141539 Cash Acquired In Connection With Reverse Recapitalization Transaction
CashAcquiredInConnectionWithReverseRecapitalizationTransaction
13000 usd
CY2020Q4 cik0000141539 Issued And Outstanding Share Capital Description
IssuedAndOutstandingShareCapitalDescription
On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021.
CY2021Q2 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
100 shares
CY2021Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
9459253 shares
CY2021Q2 cik0000141539 Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2021Q2 us-gaap Shares Issued
SharesIssued
1051028 shares
CY2021Q2 cik0000141539 Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2022Q3 cik0000141539 Accumulated Deficit
AccumulatedDeficit
4922000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70000 shares
CY2022Q2 cik0000141539 Purchase Warrants
PurchaseWarrants
100000 shares
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.5
CY2022Q2 us-gaap Investment Company Committed Capital
InvestmentCompanyCommittedCapital
550000 usd
CY2022Q2 cik0000141539 Company Raised Amount
CompanyRaisedAmount
250000 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
250000 shares
CY2022Q2 cik0000141539 Purchase Warrants
PurchaseWarrants
100000 shares
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.13
CY2022Q2 cik0000141539 Companys Service Provider Consideration Of Past Services
CompanysServiceProviderConsiderationOfPastServices
250000 usd
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2022Q2 cik0000141539 Company Raised Amount
CompanyRaisedAmount
50000 usd
cik0000141539 Royalty Percentage
RoyaltyPercentage
0.15 pure
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
100500 shares
CY2022Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
102000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
cik0000141539 Cash Acquired In The Reverse Recapitalization
CashAcquiredInTheReverseRecapitalization
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001415397
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares

Files In Submission

Name View Source Status
0001213900-22-071861-index-headers.html Edgar Link pending
0001213900-22-071861-index.html Edgar Link pending
0001213900-22-071861.txt Edgar Link pending
0001213900-22-071861-xbrl.zip Edgar Link pending
cik0000141539-20220930.xsd Edgar Link pending
ex10-1_001.jpg Edgar Link pending
f10q0922ex10-1_raphael.htm Edgar Link pending
f10q0922ex31-1_raphael.htm Edgar Link pending
f10q0922ex31-2_raphael.htm Edgar Link pending
f10q0922ex32-1_raphael.htm Edgar Link pending
f10q0922ex32-2_raphael.htm Edgar Link pending
f10q0922_raphaelpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cik0000141539-20220930_def.xml Edgar Link unprocessable
cik0000141539-20220930_cal.xml Edgar Link unprocessable
f10q0922_raphaelpharma_htm.xml Edgar Link completed
cik0000141539-20220930_pre.xml Edgar Link unprocessable
cik0000141539-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable